Gen-Probe (GPRO) Appoints Carl W. Hull as CEO
More News related to GPRO
- Xenomics, Inc. and Its Subsidiary TrovaGene, Inc. Announce HPV Patent Filing Based on Transrenal DNA Technology
- Gen-Probe to Webcast Two Upcoming Investor Presentations
- Gen-Probe (GPRO) Tops Q3 EPS by 6c; Narrows Guidance
- Gen-Probe Reports Financial Results for Third Quarter 2009
- Gen-Probe (GPRO) Gets Emergency Use Authorizaton From U.S. FDA for Prodesse ProFlu-ST Test
More News related to Management Changes
- Canaccord Adams Downgrades Golden Star Resources Ltd. (GSS) to Hold
- Barrington Downgrades Perceptron (PRCP) Following Q1 Miss
- DA Davidson Issues Mid-Day Downgrade on FEI Company (FEIC)
- D.A. Davidson Downgrades Sterling Construction (STRL) to Neutral
- BMO Capital Downgrades MF Global (MF) to Market Perform
Gen-Probe Incorporated (Nasdaq: GPRO) announced that Carl W. Hull has formally succeeded the Company's long-time leader, Henry L. Nordhoff, as chief executive officer (CEO). Mr. Hull, formerly Gen-Probe's president and chief operating officer, also has joined the Company's board of directors.
As first announced on March 23, Mr. Nordhoff retired as CEO yesterday. Mr. Nordhoff, who had served as Gen-Probe's CEO since 1994, is now non-executive chairman following his re-election to the board at the Company's annual meeting of stockholders last week.
Gen-Probe Incorporated is in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. [SM]
Related Categories
Management ChangesStocks Mentioned
-0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
